The tweet was deleted by the author.
But we saved everything 🙂.
Altimmune has released its financial results for the first quarter of 2026.
The company has provided further information and documentation on its website, giving investors and stakeholders additional insights into its recent financial performance. Details about revenue, expenses, net income, and future outlook may be found in the full report. Details are being clarified.
The company has previously highlighted clinical priorities beyond its financials. In a prior initiative, Altimmune called for early intervention and research on the link between alcohol use disorder and liver disease, as detailed in its recent clinical communication. These actions provide context to its evolving disclosures.